Uplisting – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Mon, 31 Jul 2023 21:38:41 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 Endexx Corporation Announces Uplisting to OTCQB Venture Market https://mjshareholders.com/endexx-corporation-announces-uplisting-to-otcqb-venture-market/ Mon, 31 Jul 2023 21:38:41 +0000 https://cannabisfn.com/?p=2973929

Ryan Allway

July 31st, 2023

News, Top News


CAVE CREEK, AZ, July 31, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Endexx® Corporation (OTCQB: EDXC), a provider of innovative plant-based wellness and nutritional products, announced today that it has successfully uplisted from the OTC® Pink Market to the OTCQB® Venture Market (“OTCQB”). The uplisting was processed and approved by OTC Markets Group Inc., and the Company began trading on OTCQB® July 31, 2023. Endexx® Corporation will continue to trade under the ticker symbol “EDXC”. The OTCQB® Venture Market offers investors transparent trading in entrepreneurial and development stage U.S. and international companies that may not yet qualify for OTCQX®. To be eligible, companies must be current in their reporting and must undergo an annual verification and management certification process.

“This is a significant milestone supporting the accelerated growth of Endexx® with our uplisting to the OTCQB® Venture Market,” said Davis. “This move reflects our commitment to enhancing transparency, increasing market visibility, and providing enhanced opportunities for our shareholders. Uplisting to the OTCQB® will allow us to access a broader investor base, attract institutional investors, and improve liquidity for our stock. This action demonstrates our continued growth and solidifies our position as a trusted player in the plant based consumer products and alternative vape industries.”

www.endexx.com & www.cbdunlimited.com

www.tryhyla.com

About Endexx® Corporation

Endexx® Corporation develops and distributes all natural, plant-derived wellness products and topical skincare products. Its products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness. The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and support of skin health. www.endexx.com

Hyla currently markets its proprietary non-nicotine, guarana and L-Dopa-based vape products in a wide variety of flavors. The Hyla device is the first non-nicotine vape product to be produced in this manner in the United States and provides an unprecedented 4,500 puffs per device. Hyla is currently being distributed in 11 states and 10 countries and has signed distribution agreements with an additional nine countries The Hyla vape products bear the Underwriters Laboratories global safety certification and is CE approved.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

No Offer or Solicitation. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and, where applicable, the requirements under the securities laws of any other applicable jurisdiction.

For further information, please contact:

Endexx Corporation
IR@Endexx.com
480-595-6900

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
The Healing Company Uplists to the OTCQB Venture Market and Secures New Strategic Investors https://mjshareholders.com/the-healing-company-uplists-to-the-otcqb-venture-market-and-secures-new-strategic-investors/ Thu, 06 Jul 2023 15:46:01 +0000 https://cannabisfn.com/?p=2973862

Ryan Allway

July 6th, 2023

News, Top News


  • Uplists from the OTC Pink Market to the OTCQB Venture Market; continues trading under ticker HLCO
  • Secures up to $7M in new funding from strategic partners including billion-dollar investment office of the Burman family (New Delhi) and the Goetz Family Office (Munich)
  • Including previously announced financing, brings total raised and committed equity funding  to up to $17M, alongside the $150M credit facility supporting future acquisitions

NEW YORK, July 06, 2023 (GLOBE NEWSWIRE) — The Healing Company (OTCQB: HLCO) (“The Healing Company” or the “Company”), today announced that it has successfully uplisted from the OTC Pink Market to the OTCQB Venture Market (“OTCQB”) and will continue trading under the symbol “HLCO”. Additionally, The Healing Company announced it had secured up to $7 million in new investment from strategic partners including the investment office of the Burman family, majority shareholders of one of the largest Indian consumer packaged goods (CPG) companies and the largest Ayurvedic company worldwide with a $12 billion market capitalization, as well as the esteemed German family office of Stephan and Ingvild Goetz (Munich). Including previously announced financing, this brings total raised and committed equity funding to up to $17 million, alongside the $150 million credit facility supporting future acquisitions.

The investment is intended to support the Company’s strategy of building a community of powerful healing brands through the acquisition of companies in the wellness, supplement, and nutraceutical spaces. Trading on the OTCQB Venture Market provides The Healing Company’s current and future investors with greater access to data, home country disclosure, ease of trading, and transparency. With the new funding and successful uplisting, The Healing Company is aiming for a NASDAQ listing within the next 12 months.

“The announcement of the uplisting, alongside the funding from long-term strategic investors experienced in the wellness, supplement, and nutraceutical sectors, is further validation of our business model and will support an acceleration of our accretive buy-and-build strategy. Moreover, we are confident the uplist will allow us to reach a broader investor base, and is an important stepping stone towards our goal of listing on a national exchange in the near-term. These are all exciting milestones for The Healing Company as we continue to acquire and scale health and wellbeing businesses to further our mission of bringing integrated healing to the world,” said Simon Belsham, CEO and Co-Founder of The Healing Company.

Mr. Belsham further noted, “This announcement comes on the heels of record financial performance during the fiscal third quarter, in which we achieved sequential revenue of $3.2 million, a 34% increase over the second quarter, resulting from our successful track record of acquiring and integrating complementary businesses. Your Super, our first acquisition, demonstrated profitable growth this quarter for the first time in its history. Building on this success, in March we completed the acquisition of the Chopra Global wellbeing experiences businesses which include Chopra’s physical product line, the Chopra meditation & wellbeing app, as well as licensed experiences including the award-winning Chopra Health Retreat at CIVANA Wellness Resort & Spa and the Chopra Mind-Body Zone and Spa at the Lake Nona Performance Club. Importantly, we are already seeing strong performance from the Chopra businesses. Looking ahead, we have a robust pipeline of additional acquisition targets that we believe would be both synergistic and accretive.”

The OTCQB, operated by OTC Markets Group Inc., is the premier marketplace for early-stage and developing U.S. and international companies that are committed to providing a high-quality trading and information experience for their U.S. investors. Companies must be current in their financial reporting to undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. The OTCQB quality standards provide a strong baseline of transparency as well as the technology and regulation to improve the information and trading experience for investors. The OTCQB is recognized by the Securities and Exchange Commission as an established public market providing public information for analysis and value of securities. Investors can find real-time quote and market information for the Company, once listed, at https://www.otcmarkets.com.

About The Healing Company

The Healing Company Inc. was founded with a bold aim: Bring integrated healing to the world. Compelled by the global healthcare crisis and a deep belief in a different way—one which draws on conventional medicine and ancient wisdom, science and nature—the company looks to democratize access to integrated healing methods, while helping the world evolve how it thinks about health and healthcare. To do so, the company is building a community of powerful healing brands, identifying, acquiring, and helping scale the reach and impact of the world’s highest potential healing practices & products.

The Healing Company’s common stock is quoted for trading on the OTCQB under the symbol HLCO, and its investors and advisors include global wellbeing icon Dr. Deepak Chopra, MD, renowned investor and psychedelics entrepreneur Christian Angermayer, and Social Chain & Thirdweb founder and Dragons Den member Steven Bartlett. For more information, visit http://www.healingcompany.com.

Forward-looking statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financial requirements, business strategy, products and services, potential future financings, acquisition and scaling of future brands and or project and its anticipated financing plans, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements.  Such forward-looking statements are estimates reflecting the Company’ s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements; foreign exchange and other financial markets; changes in the interest rates on borrowings; hedging activities; changes costs of goods; changes in the investments and expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which The Healing Company operates. There can be no assurance that The Healing Company will achieve the above stated brand acquisitions and scaling of those brands or the closing of any required financing. The reader should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by The Healing Company from time to time with the Securities and Exchange Commission.

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: hlco@crescendo-ir.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
UCASU jump-starts its plan of NASDAQ or NYSE up-listing in 2023 https://mjshareholders.com/ucasu-jump-starts-its-plan-of-nasdaq-or-nyse-up-listing-in-2023/ Wed, 25 Jan 2023 18:50:10 +0000 https://www.cannabisfn.com/?p=2972515

Ryan Allway

January 25th, 2023

News, Top News


January 25, 2023 – UC Asset LP (OTCQB: UCASU) management announces that the company has jump-started its plan to up-list to a major exchange, probably NASDAQ or NYSE, after it had put on hold this plan for about six months.

“Twelve months ago, we kicked off our campaign for an up-listing, and we had made solid progress toward this goal, before the dramatic change of macro-economy and stock market in general made it undesirable for us to continue the process,” explains Larry Wu, founder of UC Asset. “So we decided to freeze the plan by the end of July, 2022.”

“Despite that there are still concerns about macro-economy, as well as about the stock market, we at UC Asset have been doing well, and we have decided not to let macro-economic factors to stop us from pursuing a faster growth,” exclaims Wu.

Wu refers to the track record of the company, particularly the growth of its profit. According to its most recent annual report, the company posted net income of $0.13 per share for the year of 2021, which represented 400% growth over its $0.03 per share net income for the year of 2020. Looking forward, the management projects a $0.20 per share gross profit for the year of 2023.

Last year, the company distributed a cash dividend of $0.10 per share to its common shareholders. Management has confirmed that it will make more dividend distribution in the future.

Wu admits that the company is currently too small to justify an up-listing, as a major exchange listing will be more expensive, and will remarkably increase administration cost. Those extra cost will be difficult for a small company like UC Asset to absorb. “In order to have a meaningful uplisting, we need to increase the size of the company to at least $20 million, preferably over $30 million,” says Wu.

“Our management team has an established strategy to growth. We have identified deal pipelines with great potential, mostly of cannabis properties, for a potential portfolio expansion of $10 – $ 30 million. We have the right team to manage them. We are confident we are able to achieve the economy scale with additional capital,” Wu shares.

For this purpose, UC Asset plans to launch a SPO (secondary public offering) to raise $10 – 20 million. Wu indicates that it may also conduct a PIPE (private investment in public equity) raise prior to the SPO to raise $2 – 5 million.

“All the fund-raising will not dilute the equity of current shareholders, as our bylaw expressly prohibits the company from issuing any stocks at a price lower than the company’s net equity per share,” asserts Wu. “Particularly, we will NEVER take any investments of toxic manner, such as convertible notes of variable conversion ratios.”

“We have been very disciplined in issuing shares,” continues Wu. ” Our total issued and outstanding shares have actually decreased since our IPO, from over 5.6 million shares to less than 5.5 million shares. And last year we cancelled all our preferred units of a total number of 166,667 shares. In short, the supply of our shares is very limited, and we have adequate room to support our growth plan.”

About UC Asset LP

UC Asset LP is a limited partnership formed for the purpose of investing in real estate with innovative strategies. For more information about UC Asset, please visit: www.ucasset.com

Disclaimer:

This News Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any these statements. You are cautioned not to place undue reliance on any those forward-looking statements. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements after the date of this news release. None of such forward-looking statements should be regarded as a representation by us or any other person that the objectives and plans set forth in this News Release will be achieved or be executed.

For More Information Contact: [email protected]

Contact Details

Larry Wu

[email protected]

Company Website

http://www.ucasset.com/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market https://mjshareholders.com/clearmind-medicine-announces-closing-of-us7-5-million-public-offering-and-uplisting-to-the-nasdaq-capital-market/ Thu, 17 Nov 2022 16:48:35 +0000 https://www.cannabisfn.com/?p=2969128

Ryan Allway

November 17th, 2022

News, Top News


VANCOUVER, Nov. 17, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the closing of its underwritten public offering of 1,153,847 common shares at a price to the public of US$6.50 per share (CAD$8.65), for aggregate gross proceeds of US$7.5 million, prior to deducting underwriting discounts and offering expenses. The closing occurs following a 1-for-30 reverse stock split, which was effective at 5:30 p.m. on September 30, 2022.

In addition, the Company has granted Aegis Capital Corp. (“Aegis”) a 45-day option to purchase up to 173,077 additional common shares, equal to 15% of the number of shares sold in the offering solely to cover over-allotments, if any. The public purchase price per additional common share will be US$6.50 per share (CAD$8.65). If Aegis exercises the option in full for common shares, the total gross proceeds of the offering including the overallotment are expected to be approximately US$8.6 million before deducting underwriting discounts and commissions and offering expenses. All securities sold as part of the offering may not be sold, transferred, hypothecated or otherwise traded on or through facilities of Canadian Securities Exchange or otherwise in Canada or for the benefit of a Canadian resident until March 18, 2023.

Aegis Capital Corp. acted as sole book-running manager for the offering.

Additionally, Aegis has received 57,692 underwriter warrants, each such warrant entitling the agents to receive one common share upon payment of US $8.125 per share, exercisable six (6) months after the commencement of sales of this offering and expiring on a date which is no more than five (5) years after the commencement of sales of the offering.

A registration statement on Form F-1 (No. 333-265900) relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission (the “SEC”) on November 14, 2022. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained on the SEC’s website, www.sec.gov, or by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th Floor, New York, NY 10105, by email at [email protected], or by telephone at (212) 813-1010.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
SciSparc Provides Updates Upon Conclusion of 2021 https://mjshareholders.com/scisparc-provides-updates-upon-conclusion-of-2021/ Wed, 29 Dec 2021 21:04:45 +0000 https://www.cannabisfn.com/?p=2936417

Ryan Allway

December 29th, 2021


TEL AVIV, IsraelDec. 29, 2021 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today provides updates regarding its activities in 2021.

SciSparc Ltd. Logo (PRNewsfoto/SciSparc Ltd.)
SciSparc Ltd. Logo (PRNewsfoto/SciSparc Ltd.)

Itzhak Shrem, Chairman of the board of SciSparc, said, “We are excited to conclude a very eventful and successful year. We reached several important milestones, among them the uplisting of our ordinary shares to the Nasdaq Capital Market.”

“Looking forward to 2022, we are aiming to show progress in our clinical programs in Tourette Syndrome (TS), Alzheimer’s disease (AD) and Agitation and Autism Spectrum Disorder (ASD). We are planning on expanding our partners network and continuing to raise awareness of our unique technologies and novel treatments by showcasing them in leading events worldwide. We plan on strengthening our professional team and advisory board as well as increasing exposure to investors in North America,” added Amitai Weiss, Chief Executive Officer of SciSparc.

In 2021, the Company completed a corporate rebranding that better represent its current business focus and listed its ordinary shares on the Nasdaq Capital Market.

Financing:

During 2021, the Company raised more than $8 million from institutional and accredited investors in a private placement.

IP Protection:

During 2021, the Company was awarded two patents from the Australian Patent Office and one from the Japanese Patent Office concerning the proprietary compounds and methods underlying the Company’s core technologies: Pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

Pipeline Status:

SCI–110 for Tourette Syndrome- Towards Phase IIb Clinical Trial

During 2021, the Company announced a number of updates regarding its Phase IIb clinical study in TS using the proprietary cannabinoid-based treatment- SCI-110. The study will be led by Prof. Kirsten Mueller– Vahl from Hanover Medical School. The Company has begun preparations that will facilitate the commencement of the clinical study and engaged with a contract research organization (CRO) to provide support for the trial. In addition, SciSparc had established its supply chain infrastructure for the manufacturing and delivering of the SCI-110 drug.

Also, the Company announced the publication of a manuscript by Dr. Michael. H Bloch et al. The manuscript teaches the uses of its proprietary drug candidate SCI-110 for TS as demonstrated in a study conducted at the Department of Psychiatry, and the Child Study Center at Yale University in New Haven, Connecticut, USA.

SCI–110 for Alzheimer’s disease and Agitation- Towards Phase IIa Clinical Trial

During 2021, the Company received approval from the Israeli Ministry of Health and Helsinki Committee to commence a Phase IIa Clinical Trial of SCI-110 in patients with AD and Agitation.

The Company signed an agreement with The Israeli Medical Center for Alzheimer’s to conduct a Phase IIa clinical trial to evaluate the safety, tolerability and efficacy of SCI-110 in patients with AD and agitation using the Company’s proprietary drug candidate.

SCI–210 for Status Epilepticus

During 2021, the Company announced it has entered an agreement with The Sheba Fund for Health Services and Research, to perform a pre-clinical study for the evaluation of the Company’s SCI-210 drug development program, a proprietary novel pharmaceutical preparation containing non-psychoactive cannabinoid cannabidiol (CBD) and palmitoylethanolamide (PEA) for the treatment of Status Epilepticus (SE). The study, which is led by Prof. Nicola Maggio, a senior neurologist and a neuroscientist at the Chaim Sheba Medical Center, was already initiated after SciSparc received all the necessary approvals, including the Israeli Medical Cannabis Unit (IMCA) as well as the ethical committee approval.

SCI-160 for Pain

In 2021, the Company announced positive top-line results for its proprietary compound, SCI-160, in a controlled pre-clinical trial on neuropathic and post-operative pain. The study was conducted at the University of Calgary under the leadership of Dr. Tuan Trang, Associate Professor in the Department of Comparative Biology & Experimental Medicine, a renowned researcher in the clinical management of pain conditions.

About SciSparc (NASDAQ:SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome and for the treatment of obstructive sleep apnea; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the expected medical benefits of its therapeutics and drug candidates, its plans to expand its partners network and progress its clinical programs for TS, AD and Agitation, SE and pain, its plans to raise awareness of its technologies and novel treatments by showcasing them in leading events worldwide and its plans to strengthen its professional team and advisory board as well as increase exposure to investors in North America. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 30, 2021, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
[email protected]
Tel: +972-3-6167055

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>